The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | 3-year data of botensilimab & balstilimab in MSS metastatic colorectal cancer
Benjamin Schlechter, MD, Dana-Farber Cancer Institute, Boston, MA, explores extended follow-up results from the Phase Ib C-800-01 study (NCT03860272), evaluating botensilimab plus balstilimab in previously treated, microsatellite-stable metastatic colorectal cancer without active liver metastases. The combination produced durable responses with roughly one-third of patients alive at three years, alongside manageable toxicity, including in patients previously exposed to later-line therapies. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
